Ref ID: 18590
Author:
H. Lellek, F. Dahlke, F.A. Ayuk, C. Wolschke, N. Kr ö ger,
A.R. Zander
Author address:
Clinic for Stem Cell Transplantation (Hamburg, DE)
Full conference title:
Annual Meeting of the EBMT, 36th
Abstract:
Background: Substantial improvements of treatment against
invasive fungal infections have been achieved by the introduction of new antifungal agents including azoles (e.g. posaconazol) and echinocandins (e.g. caspofungin). However, mortality
associated with treatment-refractory aspergillosis remains high.
Preliminary data suggest that combination of azoles and echinocandins may increase activity against refractory invasive
aspergillosis (IA).
Objective: In the present study we evaluated the effi ciency and
safety of caspofungin and posaconazol for salvage therapy in
hematopoietic cell transplantation.
Patients and methods: In this monocentric, retrospective study,
32 hospitalized hematopoietic cell transplant recipients with IA
refractory to primary treatment were treated with a combination
therapy of caspofungin 1 x 50 mg and posaconazol 4 x 200 mg.
Effi cacy was assessed by clinical symptoms and the degree of
pulmonary infi ltrate regression.
Results: A favorable response was seen in the majority of
patients (78%). In two patients (6%) clinical improvement, but
no decline in pulmonary infi ltrates was observed. Five patients
(16%) did not respond to combination treatment with a fatal outcome in four of them. Combination therapy was well tolerated.
No patient discontinued treatment due to toxicity.
Conclusion: This study indicates that the combination of caspofungin and posaconazol may provide an effective and tolerable
therapy of IA in immunocompromised patients refractory to primary treatment.
Abstract Number: P787
Conference Year: 2010
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a